Area of research
Oncology · Molecular Biology
Research interest
Research interests include Pancreatic cancer, Medicine, Gemcitabine, Cancer research, In vivo, and Internal medicine.
Scribble Deficiency Promotes Pancreatic Ductal Adenocarcinoma Development and Metastasis
An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies
Contrast-Enhanced Ultrasound Algorithms (CEUS-LIRADS/ESCULAP) for the Noninvasive Diagnosis of Hepatocellular Carcinoma – A Prospective Multicenter DEGUM Study
Depletion of Macrophages Improves Therapeutic Response to Gemcitabine in Murine Pancreas Cancer
Contrast-Enhanced Ultrasound Algorithms (CEUS-LIRADS/ESCULAP) for the Noninvasive Diagnosis of Hepatocellular Carcinoma – A Prospective Multicenter DEGUM Study
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
Cytosolic 5′-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites
SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancer
Overall cellularity but not acellular stroma deposition increases gemcitabine accumulation in a genetically engineered mouse model of pancreatic cancer
Tumor associated macrophages (TAMs) scavenge gemcitabine but not 5-FU and paclitaxel in pancreatic cancer
Impact of cytosolic 5'-nucleotidase 1A on chemotherapeutic resistance in pancreatic cancer
Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer
Context-Dependent Epigenetic Regulation of Nuclear Factor of Activated T Cells 1 in Pancreatic Plasticity
Strong tumour cytidine deaminase (CDA) staining predicts for improved survival associated with sequential nab-Paclitaxel (nabP) and gemcitabine (GEM) chemotherapy as first line treatment of patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC)
A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (PDAC).
A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (mPDAC).
Metabolic Reprogramming of Fibroblasts to Enhance Gemcitabine Availability in Murine Pancreatic Cancer
Loss of P53 Function Activates JAK2–STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival
GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression
Gemcitabine uptake and metabolism of cancer associated fibroblasts in murine pancreatic cancer
Real-Time Assessment of Tissue Hypoxia <i>In Vivo</i> with Combined Photoacoustics and High-Frequency Ultrasound
SPARC independent drug delivery and antitumour effects of <i>nab</i> -paclitaxel in genetically engineered mice
Anti-Tumour Efficacy of Capecitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions
Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials